JP7100020B2 - 操作されたボツリヌス神経毒素 - Google Patents

操作されたボツリヌス神経毒素 Download PDF

Info

Publication number
JP7100020B2
JP7100020B2 JP2019510791A JP2019510791A JP7100020B2 JP 7100020 B2 JP7100020 B2 JP 7100020B2 JP 2019510791 A JP2019510791 A JP 2019510791A JP 2019510791 A JP2019510791 A JP 2019510791A JP 7100020 B2 JP7100020 B2 JP 7100020B2
Authority
JP
Japan
Prior art keywords
bont
polypeptide
domain
binding
syt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019510791A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019533430A5 (enExample
JP2019533430A (ja
Inventor
ミン ドン
リアン タオ
Original Assignee
プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ filed Critical プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ
Publication of JP2019533430A publication Critical patent/JP2019533430A/ja
Publication of JP2019533430A5 publication Critical patent/JP2019533430A5/ja
Application granted granted Critical
Publication of JP7100020B2 publication Critical patent/JP7100020B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/33—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Clostridium (G)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/24—Metalloendopeptidases (3.4.24)
    • C12Y304/24069—Bontoxilysin (3.4.24.69), i.e. botulinum neurotoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/55—Fusion polypeptide containing a fusion with a toxin, e.g. diphteria toxin
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
JP2019510791A 2016-08-24 2017-08-24 操作されたボツリヌス神経毒素 Active JP7100020B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662378967P 2016-08-24 2016-08-24
US62/378,967 2016-08-24
PCT/US2017/048508 WO2018039506A1 (en) 2016-08-24 2017-08-24 Engineered botulinum neurotoxin

Publications (3)

Publication Number Publication Date
JP2019533430A JP2019533430A (ja) 2019-11-21
JP2019533430A5 JP2019533430A5 (enExample) 2020-10-01
JP7100020B2 true JP7100020B2 (ja) 2022-07-12

Family

ID=59799485

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019510791A Active JP7100020B2 (ja) 2016-08-24 2017-08-24 操作されたボツリヌス神経毒素

Country Status (5)

Country Link
US (2) US11117935B2 (enExample)
EP (1) EP3504226A1 (enExample)
JP (1) JP7100020B2 (enExample)
CN (1) CN110072880B (enExample)
WO (1) WO2018039506A1 (enExample)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2690773C (en) * 2007-07-10 2013-09-17 Medy-Tox, Inc. Pharmaceutical liquid composition of botulinum toxin with improved stability
ES2847241T3 (es) 2012-05-30 2021-08-02 Harvard College Neurotoxina botulínica genéticamente modificada
GB201219602D0 (en) * 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
CN115925835A (zh) * 2015-03-26 2023-04-07 哈佛大学校长及研究员协会 工程改造的肉毒杆菌神经毒素
TW201718627A (zh) * 2015-06-11 2017-06-01 梅茲製藥有限兩合公司 重組梭菌神經毒素及其使用與形成方法、包括其之醫藥組合物及對應其之前驅物、編碼前驅物之核酸序列及其獲得方法與前驅物之形成方法、載體與包括核酸序列之重組宿主細胞
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
PL3481852T3 (pl) * 2016-07-08 2023-07-24 Children's Medical Center Corporation Nowa neurotoksyna botulinowa i jej pochodne
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin
US11707510B2 (en) * 2018-02-16 2023-07-25 Preclinics Discovery Gmbh Nucleic acid-based botulinum neurotoxin for therapeutic use
CN114958887B (zh) * 2021-02-26 2024-10-25 重庆誉颜制药有限公司 一种经修饰的毒素多肽的制备方法

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507073A (ja) 1999-08-25 2003-02-25 アラーガン・セイルズ・インコーポレイテッド 活性化可能な組換え神経毒
JP2008538902A (ja) 2005-04-26 2008-11-13 トキソゲン ゲーエムベーハー 神経細胞をターゲッティングするための担体
JP2015519362A (ja) 2012-05-30 2015-07-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin

Family Cites Families (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4737462A (en) 1982-10-19 1988-04-12 Cetus Corporation Structural genes, plasmids and transformed cells for producing cysteine depleted muteins of interferon-β
US4518584A (en) 1983-04-15 1985-05-21 Cetus Corporation Human recombinant interleukin-2 muteins
US5053005A (en) 1989-04-21 1991-10-01 Gary E. Borodic Chemomodulation of curvature of the juvenile spine
US5766605A (en) 1994-04-15 1998-06-16 Mount Sinai School Of Medicine Of The City University Of New York Treatment of autonomic nerve dysfunction with botulinum toxin
DE69526340T2 (de) 1994-05-09 2002-11-14 William J. Binder Botulinumtoxin ZUR REDUKTION VON Migraine -KOPFSCHMERZEN
DE69511860T2 (de) 1994-05-31 2000-02-10 Allergan, Inc. Modifizierung von clostridium-toxinen und ihre anwendung als transport proteine
GB9411138D0 (en) 1994-06-03 1994-07-27 Microbiological Res Authority Toxin assay
US6967088B1 (en) 1995-03-16 2005-11-22 Allergan, Inc. Soluble recombinant botulinum toxin proteins
GB9508204D0 (en) 1995-04-21 1995-06-07 Speywood Lab Ltd A novel agent able to modify peripheral afferent function
US5721215A (en) 1996-03-20 1998-02-24 Allergan Injectable therapy for control of muscle spasms and pain related to muscle spasms
GB9617671D0 (en) 1996-08-23 1996-10-02 Microbiological Res Authority Recombinant toxin fragments
EP1105153A4 (en) 1996-08-28 2005-01-19 Ophidian Pharm Inc POLYVALENT VACCINE AGAINST NEUROTOXIN (CLOSTRIDIUM BOTILINUM)
GB9721189D0 (en) 1997-10-08 1997-12-03 Speywood Lab The Limited Analgesic conjugates
US20080032931A1 (en) 1999-08-25 2008-02-07 Steward Lance E Activatable clostridial toxins
US6113915A (en) 1999-10-12 2000-09-05 Allergan Sales, Inc. Methods for treating pain
US20040033241A1 (en) 2000-06-02 2004-02-19 Allergan, Inc. Controlled release botulinum toxin system
AU2003237346A1 (en) 2002-05-31 2003-12-19 Thomas Jefferson University Compositions and methods for transepithelial molecular transport
US7148041B2 (en) 2003-09-25 2006-12-12 Allergan, Inc. Animal product free media and processes for obtaining a botulinum toxin
ATE533853T1 (de) 2004-02-24 2011-12-15 Allergan Inc Botulinumtoxin-screening-assays
KR100668570B1 (ko) 2004-06-28 2007-01-16 입센 리미티드 복재신경 포착에 의한 무릎 관절 통증 치료를 위한,보툴리눔 독소를 포함하는 제약 조성물
US7514088B2 (en) 2005-03-15 2009-04-07 Allergan, Inc. Multivalent Clostridial toxin derivatives and methods of their use
WO2006026780A1 (en) 2004-09-01 2006-03-09 Allergan, Inc. Degradable clostridial toxins
DE102004043009A1 (de) 2004-09-06 2006-03-23 Toxogen Gmbh Transportprotein zum Einbringen chemischer Verbindungen in Nervenzellen
CA2601592A1 (en) 2005-03-15 2006-09-28 Allergan, Inc. Modified clostridial toxins with enhanced targeting capabilities for endogenous clostridial toxin receptor systems
DK1926744T4 (en) 2005-09-19 2019-01-28 Allergan Inc CLOSTRIDIUM TOXIN-ACTIVABLE CLOSTRIDIAL TOXINES
US7985554B2 (en) 2005-10-14 2011-07-26 Wisconsin Alumni Research Foundation Botulinum neurotoxin A receptor and the use thereof
DE102005051789B4 (de) 2005-10-28 2014-08-07 Toxogen Gmbh Der Botulinus Neurotoxin A Proteinrezeptor und seine Anwendungen
FR2902341B1 (fr) 2006-06-16 2011-02-25 Scras Utilisation therapeutique simultanee, separee ou etalee dans le temps d'au moins une neurotoxine botulique, et d'au moins un derive opiace
FR2907680B1 (fr) 2006-10-27 2012-12-28 Scras Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur induite par au moins un agent anti-cancereux
FR2910327B1 (fr) 2006-12-22 2013-04-26 Scras Utilisation d'au moins une neurotoxine botulique pour traiter la douleur induite par les traitements therapeutiques du virus du sida.
EP2178905B1 (en) 2007-07-26 2013-11-06 Allergan, Inc. Methods of activiting clostridial toxins
WO2009015840A2 (en) 2007-07-27 2009-02-05 Merz Pharma Gmbh & Co. Kgaa Polypeptide for targeting of neural cells
US8586081B2 (en) 2007-09-20 2013-11-19 University Of Massachusetts Detoxified recombinant botulinum neurotoxin
WO2009042165A2 (en) 2007-09-25 2009-04-02 Thomas Jefferson University Mutant botulinum neurotoxin serotype a polypeptide and uses thereof
US20090104234A1 (en) * 2007-10-23 2009-04-23 Allergan, Inc. Methods of treating chronic neurogenic inflammation using modified clostridial toxins
RU2010120016A (ru) * 2007-10-23 2011-11-27 Аллерган, Инк. (Us) Способы лечения хронического нейрогенного воспаления с применением модифицированных клостридиальных токсинов
FR2930447B1 (fr) 2008-04-25 2010-07-30 Sod Conseils Rech Applic Utilisation therapeutique d'au moins une neurotoxine botulique dans le traitement de la douleur dans le cas de la neuropathie diabetique
JP5746624B2 (ja) 2008-08-29 2015-07-08 メルツ・ファルマ・ゲーエムベーハー・ウント・コ・カーゲーアーアー 変化した持続性を有するクロストリジウム性神経毒
TW201023928A (en) 2008-11-12 2010-07-01 Kythera Biopharmaceuticals Inc Systems and methods for delivery of biologically active agents
AU2010236613B2 (en) 2009-04-14 2016-07-07 Mcw Research Foundation, Inc. Engineered botulinum neurotoxin
US8440204B2 (en) 2009-04-30 2013-05-14 Wisconsin Alumni Research Foundation Subtype of Closteridium botulinum neurotoxin type A and uses thereof
JP6148979B2 (ja) 2010-05-20 2017-06-14 アラーガン、インコーポレイテッドＡｌｌｅｒｇａｎ，Ｉｎｃｏｒｐｏｒａｔｅｄ 分解性クロストリジウム毒素
GB201219602D0 (en) 2012-10-31 2012-12-12 Syntaxin Ltd Recombinant clostridium botulinum neurotoxins
US9216210B2 (en) 2013-12-23 2015-12-22 Dublin City University Multiprotease therapeutics for chronic pain
GB201607901D0 (en) 2016-05-05 2016-06-22 Ipsen Biopharm Ltd Chimeric neurotoxins
KR20190025906A (ko) 2016-06-08 2019-03-12 칠드런'즈 메디컬 센터 코포레이션 조작된 보툴리눔 신경독소
US11117935B2 (en) 2016-08-24 2021-09-14 President And Fellows Of Harvard College Engineered botulinum neurotoxin

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003507073A (ja) 1999-08-25 2003-02-25 アラーガン・セイルズ・インコーポレイテッド 活性化可能な組換え神経毒
JP2008538902A (ja) 2005-04-26 2008-11-13 トキソゲン ゲーエムベーハー 神経細胞をターゲッティングするための担体
JP2015519362A (ja) 2012-05-30 2015-07-09 プレジデント・アンド・フェロウズ・オブ・ハーバード・カレッジ 操作されたボツリヌス神経毒素
WO2016154534A1 (en) 2015-03-26 2016-09-29 President And Fellows Of Harvard College Engineered botulinum neurotoxin

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
Rongsheng Jin et al.，Botulinum neurotoxin B recognizes its protein receptor with high affinity and specificity，Nature，2006年，Vol.444，pp.1092-1095
Rummel, Andreas et al.，Identification of the protein receptor binding site of botulinum neurotoxins B and G proves the double-receptor concept，PNAS，2007年，Vol.104, No.1，pp.359-364

Also Published As

Publication number Publication date
CN110072880A (zh) 2019-07-30
US20220033447A1 (en) 2022-02-03
JP2019533430A (ja) 2019-11-21
RU2019108257A (ru) 2020-09-25
US11117935B2 (en) 2021-09-14
CN110072880B (zh) 2025-02-18
WO2018039506A1 (en) 2018-03-01
RU2019108257A3 (enExample) 2021-01-13
EP3504226A1 (en) 2019-07-03
US20190185524A1 (en) 2019-06-20

Similar Documents

Publication Publication Date Title
JP7100020B2 (ja) 操作されたボツリヌス神経毒素
US20220154160A1 (en) Engineered botulinum neurotoxin
JP6839239B2 (ja) 操作されたボツリヌス神経毒素
RU2789302C2 (ru) Сконструированный ботулинический нейротоксин
HK40073100A (en) Engineered botulinum neurotoxin
HK1249119B (en) Engineered botulinum neurotoxin
HK1260730A1 (en) Engineered botulinum neurotoxin
HK1260730B (en) Engineered botulinum neurotoxin

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200820

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200820

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20210420

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210611

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210621

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210917

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211118

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211206

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220303

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220603

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220620

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20220630

R150 Certificate of patent or registration of utility model

Ref document number: 7100020

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250